Sfoglia per Autore
Un commento alla lettera sulla definizione di farmaco innovativo
2012 Motola D.; Montanaro N.
Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia-Romagna region).
2013 Biagi C.; Montanaro N.; Buccellato E.; Roberto G.; Vaccheri A.; Motola D.
Ten years of pharmacovigilance in Italy: the experience of Emilia-Romagna region in the monitoring of drug’s safety profile.
2013 Melis M.; Lo Bianco S.; Biagi C.; Buccellato E.; Montanaro N.; Vaccheri A.; Motola D
Possible occurrence of paraesthesia in patients taking norethisterone: an analysis on the WHO Global Individual Case Reports database (VigiBase).
2013 Buccellato E; Biagi C; Vaccheri A; Melis M; Montanaro N; Motola D.
Dronedarone-associated acute renal failure: evidence coming from the Italian spontaneous ADR reporting database
2013 Chiara Biagi;Mauro Venegoni;Mauro Melis;Elena Buccellato;Nicola Montanaro;Domenico Motola
Comparative safety profiles of intravitreal bevacizumab, ranibizumab and pegaptanib: the analysis of the WHO database of adverse drug reactions
2014 C. Biagi;V. Conti;N. Montanaro;M. Melis;E. Buccellato;M. Donati;A. Covezzoli;R. Amato;L. Pazzi;M. Venegoni;A. Vaccheri;D. Motola
Six-year activity on approval of compassionate use of medicines by the Ethics Committee of the University Hospital of Bologna (Italy): time to update rules and recommendations
2017 Montanaro, Nicola; Melis, Mauro; Proni, Stefania; Chiabrando, Giacomo; Motola, Domenico
Non-commercial trials on medicines submitted to the Ethics Committee of the University Hospital of Bologna (Italy) along 8 years of activity: time to update rules and recommendations
2019 Montanaro N.; Bonaldo G.; Proni S.; Chiabrando G.; Motola D.
On criteria to evaluate the therapeutic innovation of drugs
2021 Motola D.; Montanaro N.
Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice
2021 Bonaldo G.; Montanaro N.; AlbertoVaccheri; Motola D.
Human papilloma virus vaccination in males: A pharmacovigilance study on the Vaccine Adverse Event Reporting System
2021 Bonaldo G.; Montanaro N.; Vaccheri A.; Motola D.
Removal of the EMA orphan designation upon request of the sponsor: cui prodest?
2021 Montanaro N.; Bonaldo G.; Motola D.
Level of therapeutic innovation from the registration studies of the new drugs for the prophylaxis of migraine
2022 Motola D.; Santi Laurini G.; Bonaldo G.; Montanaro N.
Safety profile of hydroxychloroquine used off-label for the treatment of patients with COVID-19: A descriptive study based on EudraVigilance data
2022 Motola D.; Bonaldo G.; Montanaro N.
Comparative Safety Profiles of Oncology Biosimilars vs. Originators in Europe: An Analysis of the EudraVigilance Database
2023 Nikitina, Victoria; Santi Laurini, Greta; Montanaro, Nicola; Motola, Domenico
Safety of COVID-19 vaccines in pregnancy: a VAERS based analysis
2023 Santi Laurini G.; Montanaro N.; Motola D.
Real-life safety profile of mRNA vaccines for COVID-19: An analysis of VAERS database
2023 Santi Laurini G.; Montanaro N.; Broccoli M.; Bonaldo G.; Motola D.
Safety profile of paediatric COVID-19 vaccines: An analysis of the US Vaccine Adverse Event Reporting System
2023 Nikitina V.; Santi Laurini G.; Montanaro N.; Motola D.
Safety Profile of Molnupiravir in the Treatment of COVID-19: A Descriptive Study Based on FAERS Data
2023 Santi Laurini G.; Montanaro N.; Motola D.
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile